Sitagliptin treatment increases GLP-1 without improving diabetes outcomes after total pancreatectomy with islet autotransplantation

Am J Transplant. 2019 Mar;19(3):958-959. doi: 10.1111/ajt.15119. Epub 2018 Oct 8.

Authors

Kendall R McEachron¹, Gregory J Beilman¹, Melena D Bellin²

Affiliations

¹ Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.
² Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA.

No abstract available

Keywords: autotransplantation; clinical research/practice; clinical trial; islet transplantation; translational research/science.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Case-Control Studies
Diabetes Mellitus / drug therapy*
Diabetes Mellitus / etiology
Diabetes Mellitus / pathology
Glucagon-Like Peptide 1 / metabolism*
Humans
Hypoglycemic Agents / therapeutic use
Islets of Langerhans Transplantation / adverse effects*
Pancreatectomy / adverse effects*
Pancreatic Diseases / pathology
Pancreatic Diseases / therapy*
Randomized Controlled Trials as Topic
Sitagliptin Phosphate / therapeutic use*
Transplantation, Autologous
Treatment Outcome

Substances

Hypoglycemic Agents
Glucagon-Like Peptide 1
Sitagliptin Phosphate

Grants and funding